Dogwood Therapeutics DWTX Business Segments — Research And Development Expense Clinical

Similar metrics at other companies

ALMSSingle Reportable — Research And Development Expense

$81.54M-15.6%

INBXReportable Segment — Research And Development Expense, Clinical Trials

$9.18M-30.8%

IOVASingle Reportable — Research And Development Expense

$57.37M-13.1%

CAPRSingle Reportable — Research And Development Expense

$27.38M+44.7%

OCULSingle Reportable — Research And Development Expense Other Clinical And Preclinical Programs

$758K-14.7%

AVBPSingle Reportable — Research And Development Expense Discovery Stage Programs

$12.31M-70.0%

Questions, answered.

What is Dogwood Therapeutics's business segments — research and development expense clinical?

Dogwood Therapeutics (DWTX) reported business segments — research and development expense clinical of $1.81M in Q1 2026.

How has Dogwood Therapeutics's business segments — research and development expense clinical changed year-over-year?

Dogwood Therapeutics's business segments — research and development expense clinical decreased by 0.4% year-over-year, from $1.82M to $1.81M.

What is the long-term trend for Dogwood Therapeutics's business segments — research and development expense clinical?

Over 2 years (2023 to 2025), Dogwood Therapeutics's business segments — research and development expense clinical has grown at a 703.9% compound annual growth rate (CAGR), from $112.2K to $7.25M.

What does business segments — research and development expense clinical mean?

Represents the costs incurred for conducting clinical trials and human studies to evaluate the safety and efficacy of drug candidates. This metric is critical for biotechnology companies as it tracks the primary investment required to advance a therapeutic through the regulatory approval pipeline.